Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus
1 finding from 1 review
Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus
1 finding from 1 review
Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus
1 finding from 1 review
Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Azole showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Griseofulvin probably leads to higher adverse events compared with azole (moderate certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Griseofulvin may leads to higher adverse events compared with terbinafine (low certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Combination terbinafine plus azole showed no clear difference in adverse events compared with terbinafine monotherapy (low certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Azole showed no clear difference in adverse events compared with terbinafine (moderate certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Terbinafine showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review